Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
Some key findings from scientific literature include
Metabolism After food is ingested, cobalamin is released in the stomach by peptic digestion and bound to a gastric R-protein (also called haptocorrin) to form an unattackable complex [2]
Unlike most peptides, BPC-157 demonstrates notable stability in acidic environments, which has led researchers to study its oral administration route particularly for gastrointestinal applications
The rendered product page includes the compound title, product description, selected vendor panel, price and pack-size information, discount code controls when available, trust badges, accepted payment notes, delivery expectations, third-party verification references, product images, related articles, research disclaimers, and navigation back to other PeptideStack resources
